A large review and meta-analysis found that, among people with autism spectrum disorder, their most significant impairments were with theory of mind and emotional perception/processing. (JAMA Psychiatry)
People with cerebral palsy without intellectual disability were more likely than non-palsied individuals to experience anxiety or depression. (JAMA Neurology, MedPage Today)
Teens and young adults who visited the emergency department for certain conditions — epilepsy or seizures, pain, syncope, vomiting, or an injury inflicted by someone else — were more likely to self-harm. “An awareness of these patterns may help guide screening efforts for suicide prevention in clinical settings,” wrote the researchers in the American Journal of Preventive Medicine.
A study of over 2,000 kids found social aggression peaked from ages 1.5 to 3.5 and then dropped off until the age of 13. (JAMA Network Open)
Luye Pharma said it won’t need pediatric clinical studies for its extended release risperidone injection LY03004 (Rykindo) for schizophrenia, after reaching agreement with the FDA.
Researchers identified a protein in the amygdala that, when overactivated, may play a role in anxiety disorders. (Nature Communications)
The investigational acute agitation treatment BXCL501 — a sublingual film of dexmedetomidine — was granted fast track designation by the FDA, the maker BioXcel Therapeutics announced.
In related news, the FDA granted priority review to Heron Therapeutic’s bupivacaine/meloxicam pain management drug HTX-011.